What's our role?

We aim to:

  • drive the uptake and adoption of innovation in the NHS
  • identify and support innovations that will deliver the most benefits for patients
  • streamline existing activities for high potential, innovative products
  • develop new and different ways of working to speed up processes.

Who we are

NHS England and NHS Improvement host the new Accelerated Access Collaborative (AAC).

The AAC board, chaired by Lord Darzi, includes representation from the following patient groups, government bodies, industry and NHS bodies:  

  • NHS England / NHS Improvement
  • the Department of Health and Social Care
  • the Department for Business, Energy and Industrial Strategy
  • the National Institute for Health and Care Excellence
  • the Medicines and Healthcare products Regulatory Agency
  • the Academic Health Science Networks
  • the Association of British Pharmaceutical Industries
  • the Association of British HealthTech Industries
  • the Association of Medical Research Charities
  • NHSX
  • the BioIndustry Association
  • National Voices.

The AAC has established a new dedicated unit within NHS England and NHS Improvement. It's responsible for coordinating activities across the various AAC partner organisations and driving forward the AAC’s priorities.

The unit has an integrated innovation and medicines senior management team in NHS England and NHS Improvement. This brings together the coordination of medicines policy, commercial agreement and broader innovation policy and delivery. In May 2019, Dr Sam Roberts was announced as the AAC’s new chief executive.

Our key deliverables

The AAC has 6 key deliverables for 2019/20, which were agreed by the AAC board in June 2019. The AAC has aligned these to the priority areas of focus for the board:

  • launch of a portal signposting funding, advisory support, and evidentiary requirements to innovators
  • bespoke support of categories of early-stage products
  • launch of a single horizon-scanning platform across all partners
  • pilot expanded real-world testing within NHS, leveraging private capital
  • significant spread of AAC rapid uptake products, innovation and technology payment products, and academic health science networks national programmes
  • implementation of the funding mandate for devices, diagnostics and digital products.

How will we measure our success?

To ensure that our support remains effective, the AAC will continuously monitor and evaluate the effectiveness of its support. At its June 2019 meeting, the AAC board agreed an interim approach to measuring its impact during 2019/20. This includes measuring the uptake, clinical outcomes and calculated return on investment for AAC designated products.

By 2020, the AAC will ensure that its longer-term approach to measuring its success aligns with existing and evolving innovation measures. This will be key to measuring the AAC’s contribution in making the NHS one of the most pro-innovative in the word.

How are we governed?

The AAC is made up of the board and steering group.

AAC board

This comprises the most senior representatives from the AAC partner organisations, the health technology industry and clinical, research and patient representatives. The board is accountable to the Minister for Health.

The board decides which products we'll support and oversees the acceleration progress of the designated products.

AAC steering group

This is made up of senior-level representatives from the Academic Health Science Networks, Medicines and Healthcare products Regulatory Agency, NHS England, NHS Improvement, National Institute  for Health and Care Excellence, National Institute for Health Research, Department of Health and Social Care and Department for Business, Energy and Industrial Strategy. They identify and shortlist products and make recommendations to the board on which products should receive support. They also agree to activities needed to accelerate the progress of those products.